Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions

Abstract

A study was conducted to examine the feasibility of cisplatin‐based chemotherapy in elderly patients (75 years old) with advanced non‐small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Thirty‐four patients were enrolled between September 1993 and December 1994. Patients with normal organ function and good performance status (PS) received cisplatin‐based chemotherapy (cisplatin 80 mg/m² on day 1 and vindesine 3 mg/m² on days 2 and 8 for NSCLC, or cisplatin 80 mg/ m² on day 1 and etoposide 100 mg/m² on days 2 to 4 for SCLC). Ten patients (29%) were eligible for this study, 7 with NSCLC and 3 with SCLC. Reasons for exclusion were ischemic heart disease in 14, poor PS (2) in 11, reduced creatinine clearance (Ccr) in 10, abnormal electrocardiogram without ischemia in 9 and noncompliance with the protocol in 2 patients. Eight patients had two or more reasons. Nine of the 10 eligible patients were able to tolerate 2 or more courses of chemotherapy. All 3 patients with SCLC responded (1 complete response and 2 partial response), but only 1 of the patients with NSCLC achieved partial response. Toxicity was evaluated according to Japan Clinical Oncology Group criteria. All but one patient experienced grade 4 neutropenia, and 6 patients had infectious episodes requiring antibiotics. Grade 3 anemia and thrombocytopenia were observed in 1 and 2 patients, respectively. Non‐hematological toxicities were mild. Only 10 of 34 patients (29%) satisfied our eligibility criteria and they experienced severe myelotoxicity. We conclude that chemotherapy should be given carefully to elderly patients even if they appear to have normal organ function.